Navigation Links
China Yongxin Pharmaceuticals, Inc. Announces 2008 Fourth Quarter and Full Year Financial Results
Date:4/23/2009

istribution, 343 of these were granted exclusive distribution rights in Jilin province.

Operating expenses, which include selling, general and administration expenses for fiscal year 2008, were $6.1 million, up 57.7% compared to the same period in 2007. Selling expenses for the period increased to approximately $3.6 million from $2.6 million in 2007, which is a result of increased marketing efforts. General and administrative expenses increased to $2.6 million in 2008 from $1.3 million in 2007. The increase was mainly due to the increased expenses related to the public market.

Operating income totaled approximately $5.8 million, a 40.5% increase from the $4.1 million reported for fiscal year 2007. Operating margins were 9.8% and 8.6% for the fiscal year 2008 and 2007, respectively.

For fiscal 2008, net income was approximately $4.1 million, an increase of 13.7% from $3.6 million recorded for fiscal 2007. The provision for income taxes was $1.0 million and $17,888, yielding an effective tax rate of 16% and 0.4% for 2008 and 2007 respectively and thus impacted the year-over-year net income comparison.

Fully diluted earnings per share for 2008 and 2007 were $0.13 and $0.16 respectively, based on 31.2 million and 22.4 million shares for 2008 and 2007, respectively. This increase in outstanding shares was related to recapitalization on reverse merger. The share count does not include 5 million shares of preferred stock owned by the management, which is convertible to up to 30 million shares of common stock.

"We are very pleased with our strong financial performance in 2008 despite the global recession as growth emanated from increased sales through our pharmaceutical wholesale business to a larger base of customers complemented by higher margin products in addition to contributions from our retail chain drugstores where we launched 14 new locations during 2008," commented Mr. Yon
'/>"/>

SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. China Breaks Ground on Largest Comprehensive Stem Cell Storage and Processing Facility
2. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
3. HUYA Bioscience Announces Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China
4. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
5. China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results
6. China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Results
7. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
8. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
9. China Agri-Business Announces 2008 Operating Results
10. China Biologic Products Announces Strong 2008 Results
11. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... TX (PRWEB) December 17, 2014 Achim ... and administration for Stoller Group. In this position, Noack ... Group, on administrative matters, develop marketing strategy and supervise ... services. , “Achim has tremendous knowledge and experience ... of Stoller Group. “His experience and innovative thinking will ...
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... SPRING, Md. , Dec. 17, 2014  United ... two senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics ... to President and Co-Chief Executive Officer and David ... Operating Officer.  In connection with these promotions, Dr. Rothblatt,s ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... June 2, 2011 Morphotek®, Inc., a subsidiary of ... multi-center, phase II study of MORAb-004 for the treatment ... potentially first-in-class monoclonal antibody that specifically binds to endosialin/tumor ... its safety and therapeutic activity at two dosages. ...
... Calif., June 2, 2011 Life Technologies Corporation ... performed in cooperation with the University Hospital Muenster, Germany, on ... bacterium at the root of the deadly outbreak in Germany ... strains. The data obtained from the DNA ...
... electrodes have been coated with a drug-loaded polymer in ... a number of neurological symptoms, such as those associated ... In a study published today, 2 June 2011, ... researchers have developed a novel technology to precisely modulate ...
Cached Biology Technology:Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 3DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak 2DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak 3DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak 4New technology could inspire brain implant for detecting and treating seizures 2
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... , The bottled water, soda pop, or micro brew-beer that ... cities contains a natural chemical imprint related to geographic location. ... imprint in your hair that could be used to track ... believed to be the first concerted effort to describe the ...
... looking for new antibiotics: A new research published in the ... ( http://www.fasebj.org ) explains for the first time how honey ... protein that they add to the honey, called defensin-1, which ... infections and to develop new drugs that could combat antibiotic-resistant ...
... WEST LAFAYETTE, Ind. - Fast-food restaurants can supersize French ... to supersize a type of apple. Peter Hirst, a ... in some Gala apple trees causes some apples to grow ... reported in the current issue of the Journal of ...
Cached Biology News:Beverages leave 'geographic signatures' that can track people's movements 2Honey as an antibiotic: Scientists identify a secret ingredient in honey that kills bacteria 2Apples grow larger when cells don't divide, study shows 2
... Kit is based on quantification of the ... and free orthophosphate. The rapid color formation ... on a spectrophotometer (600-660 nm) or on ... kits have been optimized to offer superior ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... The desk-top XCAT 50 X-Ray System from KUBTEC ... to provide two and three dimensional representation of ... provides volumetric reconstruction of specimen X-ray images, the ... provide high level of detail in standard 2D ...
... BTX, the leader in electroporation products and ... innovative product line for experiment optimization and ... is a breakthrough in Molecular Delivery. The ... procedures that typically limited the number of ...
Biology Products: